Research programme: beta thyroid hormone receptor agonists - Viking Therapeutics

Drug Profile

Research programme: beta thyroid hormone receptor agonists - Viking Therapeutics

Alternative Names: MB-10866; TR-beta agonists - Viking; VK 0214

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Metabasis Therapeutics
  • Developer Kennedy Krieger Institute; Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adrenoleucodystrophy; Dyslipidaemias; Hyperlipidaemia; Non-alcoholic steatohepatitis

Most Recent Events

  • 06 Dec 2016 VK 0214 receives Orphan Drug status for Adrenoleucodystrophy in USA
  • 26 Sep 2016 Positive pharmacodynamics data from a preclinical study in Adrenoleucodystrophy released by Viking Therapeutics
  • 26 Jul 2016 Preclinical data released by Viking Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top